- Zacks•17 days ago
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.
- GlobeNewswire•2 months ago
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids
THE WOODLANDS, Texas, Jan. 30, 2017-- Repros Therapeutics Inc. ® today announced the FDA has granted an“ end of Phase 2” meeting to discuss the Phase 3 requirements to demonstrate both efficacy and safety ...
- Zacks•3 months ago
Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.
ZONN.BE : Summary for REPROS THERAP.NEW DL-,001 - Yahoo Finance
REPROS THERAP.NEW DL-,001 (ZONN.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
As of 8:08AM CET. Market open.
People also watch
|Day's Range||1.06 - 1.06|
|52 Week Range||1.06 - 1.15|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|